Oruka Therapeutics, INC 10-Q quarterly reports

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $30.3 million for Q3 2025, while advancing its lead programs ORKA-001 and ORKA-002 and securing $169.6 million in new financing.

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported increased losses in Q2 2025 as it advances its lead psoriasis programs, ORKA-001 and ORKA-002, into clinical trials.

Oruka Therapeutics reports a net loss of $21.0 million for the first quarter of 2025, focusing on the development of novel monoclonal antibody therapeutics.

Oruka Therapeutics reports its financial results for the quarter ended September 30, 2024, highlighting a significant PIPE financing and progress in its clinical development programs.

ARCA Biopharma has entered into a merger agreement with Oruka Therapeutics, planning to dispose of its legacy assets and issue a special dividend to existing shareholders.

ARCA Biopharma has entered into a merger agreement with Oruka Therapeutics, while also reporting a net loss of $2.009 million for the first quarter of 2024.